Gilead May Move Ahead of Rivals With Hepatitis C Results

Gilead Sciences Inc. may have an edge on rivals developing new hepatitis C drugs for a potential $20 billion market after a study showed its experimental drugs cleared the liver disease virus in 100 percent of patients.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.